Cavernous sinus involvement in human papillomavirus associated oropharyngeal squamous cell carcinoma: case report of an atypical site of distant metastasis

David Forner 1*, Derek Wilke 2, Matthew H. Rigby 3, Sidney Croul 3, Anuradha Mishra 4, Emad Massoud 1,5, David B. Clarke 5,1,4 and Nathan Lamond 6

Abstract

Background: HPV-associated OSCC (HPV-OSCC) has been determined to be a distinct disease entity from non-HPV associated OSCC. Patients affected by HPV-OSCC generally have a more favourable prognosis, with improved rates of locoregional control and survival compared with their non-HPV counterparts. Despite this, HPV-OSCC has a similar rate of distant metastases. Interestingly, recent evidence has emerged that demonstrates more frequent atypical metastasis patterns when compared to non-HPV associated disease. To the best of our knowledge, this report describes the first case of a confirmed HPV-OSCC with distant metastasis to the cavernous sinus.

Case Presentation: A 62-year-old non-smoking male presented to the head and neck oncology clinic with a five-month history of enlarging right neck mass causing neck pain, dysphagia, and dysphonia. HPV-associated base of tongue squamous cell carcinoma (cT4aN2c) was diagnosed, and he was treated with primary chemoradiation. Shortly after treatment, he presented with progressive bilateral cranial nerve palsies including left cranial nerve III and right cranial nerve VI involvement. Imaging identified masses in the left cavernous sinus with extension of tumor into the sella and in the right cavernous sinus at the level of Dorello’s canal. Endoscopic Image Guided Transsphenoidal biopsy of the left sellar mass confirmed distant metastases from the previously treated HPV-OSCC primary to the cavernous sinus. The patient was palliated with carboplatin and paclitaxel.

Conclusion: The presented report is the first documented case of confirmed HPV-associated oropharyngeal squamous cell carcinoma metastasizing to the cavernous sinus, and the only HPV confirmed head and neck cancer case to present with metastasis to the cavernous sinus and limited extracranial disease. This case demonstrates the importance of recognizing presentations of atypical metastasis that are possible in HPV-associated oropharyngeal cancer. Given the rarity of metastasis to this region, vigilance in follow up is instrumental in early identification and treatment for these patients.

Keywords: Human papillomavirus, Oropharyngeal squamous cell carcinoma, Cavernous sinus, Cranial nerve palsy

* Correspondence: david.forner@dal.ca
1Division of Otolaryngology – Head & Neck Surgery, Department of Surgery, Queen Elizabeth Health Science Center, Dalhousie University, Third Floor Dickson Building, Victoria General Site, 820 University Avenue, Halifax B3H 1Y9, NS, Canada
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Oropharyngeal squamous cell carcinoma (OSCC) has traditionally been associated with tobacco and alcohol use. In the past, these exposures accounted for up to 75% of cases [1]. Public health initiatives have reduced smoking and alcohol consumption and resulted in a decline in head and neck cancers in general over the past three to four decades [2], yet rates of OSCC have continued to rise [3, 4]. The increased incidence of OSCC has been attributed to a growing proportion of diagnoses associated with infection by the human papillomavirus (HPV) [4]. This holds true in Canada as well, with an increase from 47% of oropharyngeal cancer cases being HPV-associated in 2000, to nearly 75% in 2012 [5].

HPV-associated OSCC (HPV-OSCC) has recently been recognized to be a distinct disease entity from OSCC occurring in the absence of HPV infection. Human papillomavirus association is most commonly identified with p16 immunohistochemistry, whereby HPV-OSCC cells display p16-positivity. In general, HPV-OSCC is associated with a more favourable prognosis when compared to OSCC occurring in the absence of HPV infection, with improved rates of locoregional control and patient survival following curative-intent treatment of localized disease [6]. Despite this more favourable prognosis, HPV-OSCC carries a similar risk of distant metastases of approximately 10% at three to five years [7, 8]. In addition, recent evidence demonstrates HPV-OSCC may also lead to atypical patterns of metastases. The most common sites of distant metastases in OSCC, regardless of HPV status, include lung, lymph nodes, bone and liver [9, 10]. However, HPV-OSCC has also resulted in atypical patterns, including dural metastasis [11], osseous metastases 11 years after initial treatment [12], and multiple brain metastases [13]. These findings are not limited to case reports, with retrospective reviews similarly suggesting that metastases amongst patients with HPV-related disease are more likely to include unusual sites [14]. Furthermore, studies examining long-term outcomes of distant metastases in HPV-OSCC have identified distinct “disseminating” phenotypes, with metastases to multiple sites, and “explosive” phenotypes, with complete organ involvement [15]. Finally, compared to non-HPV associated disease, patients with HPV-OSCC are more likely to experience late distant metastases, with disease appearing after two to three years [15].

To the best of our knowledge, this report describes the first case of a confirmed HPV-OSCC with distant metastasis to the cavernous sinus. We intend for this report to highlight the importance of recognizing presentations of atypical metastasis that are possible in HPV-associated oropharyngeal cancer.

Case presentation

A 62-year-old male lifelong non-smoker was referred to the head and neck oncology clinic with a five-month history of enlarging right neck mass associated with neck pain, dysphagia, and dysphonia. He was otherwise healthy, aside from type II diabetes mellitus and a distant history of sarcoidosis. Physical examination, as well as contrast-enhanced CT scan of the neck, showed a large base of tongue mass that crossed the midline and projected into the suprathyroid epiglottis. There was a 4.6 × 3.4 cm mass representing a necrotic confluence of lymph nodes in right level IIA and IIB. Biopsy confirmed non-keratinizing, HPV-OSCC. Immunohistochemistry p16 testing was used for HPV diagnosis. PET/CT scan demonstrated bilateral level III lymphadenopathy, but did not show evidence of distant metastases. The patient was diagnosed with a cT4aN2c HPV-OSCC and referred to the institutional tumor board where a recommendation for definitive chemoradiation was made. Staging was according to the American Joint Committee on Cancer Seventh Edition. The patient received 70 Gy in 35 fractions to the primary site and involved nodes, with 56 Gy to the uninvolved regional nodes bilaterally, including the bilateral retropharyngeal nodes. Due to the patient’s comorbidities the concurrent chemotherapy consisted of intravenous cetuximab given as a loading dose of 400 mg/m² one week prior to the initiation of radiotherapy, followed by seven weekly doses of 250 mg/m² concurrent with radiotherapy. During and soon after completing chemoradiotherapy, the patient experienced the expected toxicities and had evidence of favourable cancer response to treatment. A contrast enhanced CT scan of the neck performed five weeks after completion documented good anatomic response to treatment with resolution of all disease with the exception of a lymph node within right level II, which was much decreased in size, measuring 2 cm in greatest dimension.

Two months after completing chemoradiotherapy, the patient presented to medical attention with onset of binocular vertical diplopia. He was found to have subtle evidence of a new pupil-sparing, left-sided cranial nerve III palsy. His extracocular movement deficits progressed rapidly over one and a half weeks and upon repeat examination he was found to have a new right-sided cranial nerve VI palsy. Differential diagnosis included ischemia, neuromuscular disorder, metastasis, unrelated compressive lesion, and bilateral aneurysm. He was admitted to hospital for investigations. Electromyography showed no evidence of myasthenia or myopathy. Magnetic Resonance Imaging of the sella revealed two separate enhancing cavernous sinus lesions; one tumor in the left cavernous sinus that encased the internal carotid artery with extension into the sella (Fig. 1) and another involving the right cavernous sinus and clivus at the level of Dorello’s canal. PET/CT scan demonstrated resolution of
his original primary tumor and cervical lymphadenopathy, suggesting complete metabolic response within the chemoradiotherapy field (Fig. 2a). However, intense focal FDG uptake was demonstrated within the aforementioned two cavernous sinus lesions (Fig. 2b) as well as FDG uptake within a new 1 cm hypodensity within segment 4A of the liver.

The patient underwent Endoscopic Image Guided Transsphenoidal biopsy of the sellar tumor which showed a malignant basaloid tumor consistent with non-keratinizing p16-positive squamous cell carcinoma, likely of oropharyngeal origin (Fig. 3) and consistent with early distant metastases from his HPV-OSCC. Discussion with both radiation oncology and medical oncology was held, outlining the poor prognosis associated with metastatic head and neck cancer. The patient began palliative chemotherapy with carboplatin and paclitaxel, and has tolerated this well, with mild improvement in his symptoms in the form of improved extraocular eye movement and return of left eye vision.

Discussion
Metastases involving the cavernous sinus are rare and have previously been described in several solid tumors. Cancers with primary tumors outside of the head and neck have been shown to occasionally metastasize to the cavernous sinus, including carcinomas of the lung [16], colon [17, 18], and liver [19]. Head and neck cancers have also been described to metastasize to the cavernous sinus, including squamous cell carcinomas with laryngeal primaries [20], papillary thyroid cancer [21], and facial tumors [22, 23].

Two cases of oropharyngeal squamous cell carcinoma with metastasis to the cavernous sinus have been recently described. In one, disease progression was advanced on initial presentation, with a relatively small primary tumor but substantial nodal involvement and lung metastases (cT1N2bM1). In the other, nodal involvement was also extensive on the patient’s initial presentation, with N2c disease. There were no additional sites of metastasis in that case. However, no HPV testing or smoking histories were reported in either case, calling into question the nature of the cancer [24, 25]. Wirth and colleagues [26] highlighted an HPV confirmed squamous cell carcinoma of oral cavity origin with post-treatment metastasis to the cavernous sinus.

Fig. 1 MRI scan of cavernous sinus mass. Coronal post-gadolinium enhanced T1 MRI scan demonstrating soft tissue mass involving the left cavernous sinus and encasing the left internal carotid artery (arrows); note deviation of the hypothalamic-pituitary stalk to the right (*)

Fig. 2 PET scan demonstrating resolution primary tumor and new sella lesion. PET demonstrating a metabolic resolution of the primary tumor and b intense focal FDG uptake within the left sella
sinus presenting as diplopia, ptosis, and ophthalmoplegia. In that case, the tumor involvement was extensive (pT4N2c disease) with surgical and adjuvant chemoradiation treatments. However, the association of HPV and oral cavity cancer is under debate, and it remains unclear whether HPV-associated oral cavity cancer should be considered a distinct disease entity from non-HPV associated disease as is considered the case for oropharyngeal cancer [27]. The currently presented case is therefore the first documented report of confirmed HPV-OSCC to the cavernous sinus.

HPV-associated oropharyngeal cancer is considered to be a distinct disease entity and therefore has a different natural history and prognosis compared to non-HPV associated oropharyngeal cancer. Locoregional control and overall survival of HPV patients is better, with long term survival approaching an improvement of over 40%. However, a subset of patients develop early, widespread metastases and fair very poorly [6]. As well, rare, atypical sites of distant metastasis are more common in HPV-associated disease. As was the case in our patient, extensive nodal disease on presentation is common in HPV-associated oropharyngeal cancer, and has been determined to be a predictor of poor outcomes and shorter disease-free survival [28]. Extensive smoking history has also been proposed as a predictor of poor outcomes in HPV-OSCC [7]. The patient in the current report was a lifetime non-smoker, and unfortunately developed distant metastasis. This highlights that although our ability to predict disease outcome is improving [7, 28, 29], work still remains to determine which patients may suffer from these early metastases.

Although outcomes differ, treatment of HPV-OSCC currently aligns with that of non-HPV OSCC and may include surgical resection, radiation therapy alone, or chemoradiation. Among head and neck cancer populations unselected for HPV status, the evidence supporting the addition of concurrent chemotherapy using either cisplatin or cetuximab has shown definitive improvements in overall survival and locoregional control rates compared with definitive radiation alone [30, 31]. However, the rate of distant metastases was not significantly improved by concurrent treatment in these studies. Recent studies also suggest improved outcomes and overall survival with the addition of concurrent chemotherapy using either cisplatin or cetuximab to radiation therapy in locoregionally advanced HPV-OSCC, specifically [28, 32]. While high-dose cisplatin may result in improved distant metastases rate in HPV-OSCC [28], there remain no data to suggest that concurrent cetuximab results in significant improvement in distant metastases rate over definitive radiotherapy alone. Despite the addition of concurrent cetuximab in the patient presented here, distant metastasis occurred rapidly.

---

**Fig. 3** Histology sections of sellar lesion. Biopsy of sellar tumor demonstrating non-keratinizing p16 squamous cell carcinoma. Immunohistochemistry demonstrating: a poorly differentiated cancer with squamous differentiation; b immunohistochemistry demonstrating diffuse p16 positivity; and c diffuse p63 positivity.
The cavernous sinuses are paired dural venous sinuses that contain, either running directly through or within the lateral wall, cranial nerves III, IV, V₁, V₂, and VI, as well as the internal carotid artery. Due to these anatomic relationships, lesions of the cavernous sinus may present with headache, chemosis, ophthalmoplegia, proptosis, miosis, diplopia, or sensory deficits in the ophthalmic and maxillary nerve distributions. Indeed, cavernous sinus metastases are capable of presenting with these signs and symptoms, and recognition of this pattern is necessary in HPV-OSCC patients as this disease has shown a propensity for atypical metastases. Metastasis to this region is rare, and having two separate metastatic tumors of the cavernous sinuses become simultaneously symptomatic was indeed extraordinary. Vigilance in close follow up of newly symptomatic patients is instrumental for early identification of tumor metastasis and for treating these patients.

**Conclusion**

The presented report is the first documented case of confirmed HPV-associated oropharyngeal squamous cell carcinoma metastasizing to the cavernous sinus, and the only HPV confirmed head and neck cancer case to present with cavernous sinus involvement in the absence of widespread metastases. This case demonstrates the importance of recognizing presentations of atypical metastasis that are possible in HPV-associated oropharyngeal cancer.

**Abbreviations**

CT: Computed tomography; HPV: Human papillomavirus; HPV-OSCC: Human papillomavirus associated oropharyngeal squamous cell carcinoma; OSCC: Oropharyngeal squamous cell carcinoma; PET: Positron emission tomography

**Availability of data and materials**

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Data sharing is unavailable for this study as it would compromise patient privacy. However, further information regarding the case is available, within limits of patient privacy, upon request.

**Authors’ contributions**

DF gathered data, prepared the initial manuscript draft, and approved the final draft. All other authors contributed to patient care, offered expert advice on manuscript preparation, and approved the final draft. NL was the principal investigator and approved the final draft.

**Ethics approval and consent to participate**

This case report was performed under the Nova Scotia Health Authority Research Ethics Board guidelines for case reports. No formal research ethics board approval was necessary and therefore no reference number was generated.

**Consent for publication**

Informed consent from the patient was obtained for dissemination of this case in accordance with the Nova Scotia Health Authority research ethics board guidelines.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48(11): 3282–7.
2. Näsman A, Attner P, Hammarstedt L, Du, J, Eriksson G, Graud G, Åhrlund-Richter S, Marklund L, Romanstian M, Lindquist D. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125(2):362–6.
3. Auluck A, Hislop G, Badik J, Poh C, Zhang L, Rosin M. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer. 2010;116(11):2635–44.
4. Johnson-Obaseki S, McDonald JT, Costen M, Rourke R. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg. 2012;147(1):74–8.
5. Habbous S, Chu KP, Lau H, Schor M, Belayneh M, Ha MN, Murray S, O’Sullivan B, Huang SH, Snow S. Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. Can Med Assoc J. 2017;189(32):E1830–40.
6. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Rabin A, Galloway T. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014; https://doi.org/10.1200/JCO.2014.352.9229.
7. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Wess WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
8. O’Sullivan B, Huang SH, Perez-Ordonez B, Massey C, Siu LL, Weinreb I, Hope A, Kim J, Bayley AJ, Cummings B, et al. Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radither Oncol. 2012;103(3):49–56.
9. Marioni G, Doro D, Marino F, Verdecchia P, Staffieri C, Staffieri A. Skin and eye: uncommon sites of distant metastasis from tongue base squamous cell carcinoma. Acta Otolaryngol. 2003;123(9):1110–4.
10. Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mordon V. Incidence and sites of distant metastases from head and neck cancer. Otolaryngol Head Neck Surg. 2001;125(4):202–7.
11. Al-Ramli S, Cross S, Chen Y, Nizzi T, Greenschloff JF, Lorenzo R, Buchy BB, Adelstein DJ, Koyfman SA. Solitary dural metastasis at presentation in a patient with untreated human papillomavirus-associated squamous cell carcinoma of the oropharynx. Head Neck. 2014;36(10):E103–5.
12. Ley J, Wildes T, El-Mofty S, Adkins D. Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma. Eacancermedicalscience. 2014;8:480.
13. Ruzevick J, Olivi A, Westra WH. Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer. J Neuro-Oncol. 2013;112(3):449–54.

14. Huang SH, Perez-Ordonez B, Liu F-F, Waldron J, Ringash J, Irish J, Cummings B, Siu LL, Kim J, Weinreb I. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2012;81(1):276–83.

15. Huang SH, Perez-Ordonez B, Weinreb I, Hope A, Massey C, Waldron JN, Kim J, Bayley AJ, Cummings B, Cho BJ. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013;49(1):79–85.

16. Mills RP, Insalaco SJ, Joseph A. Bilateral cavernous sinus metastasis and ophthalmoplegia: case report. J Neurosurg. 1981;55(3):463–6.

17. Öneç B, Öksüzoglu B, Hatipoğlu HG, Öneç K, Azak A, Zengin N. Cavernous sinus syndrome caused by metastatic colon carcinoma. Clin Colorectal Cancer. 2007;6(8):593–6.

18. Supler ML, Friedman WA. Acute bilateral ophthalmoplegia secondary to cavernous sinus metastasis: a case report. Neurosurgery. 1992;31(4):783–6.

19. Aung T, Po Y, Wong W. Hepatocellular carcinoma with metastasis to the skull base, pituitary gland, sphenoid sinus, and cavernous sinus. Hong Kong Med J. 2002;8(1):48–51.

20. Zahra M, Tewfik HH, McCabe BF. Metastases to the cavernous sinus from primary carcinoma of the larynx. J Surg Oncol. 1986;31(1):69–70.

21. Takami T, Ohata K, Tsuyuguchi N, Maa Y, Inoue Y, Wakasa K, Hara M. Cavernous sinus metastasis from thyroid papillary adenocarcinoma. J Clin Neurosci. 2002;9(5):598–600.

22. Woodruff WR Jr, Yeates A, McLendon R. Perineural tumor extension to the cavernous sinus from superficial facial carcinoma: CT manifestations. Radiology. 1986;161(2):395–9.

23. Tsuda H, Ishikawa H, Asayama K, SAITO T, ENDO S, Mizutani T. Abducens nerve palsy and Horner syndrome due to metastatic tumor in the cavernous sinus. Intern Med. 2005;44(6):644–6.

24. Marchese-Ragona R, Maria Ferraro S, Marioni G, Staffieri C, Manara R, Restivo DA, Staffieri A. Abducens nerve palsy and Horner syndrome due to metastasising tumour in the cavernous sinus. Intern Med. 2005;44(6):644–6.

25. González García R, Sastre Pérez J, Naval Gías L, Rodríguez Campo FJ, Díaz González FJ. Cavernous sinus metastasis from oropharyngeal squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2007;12(2):166–70.

26. Wirth LJ, Plotkin SR, Emerick KS, Faquin WC. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer. N Engl J Med. 2012;367(12):1136–47.

27. Hübbers CU, Akgül B. HPV and cancer of the oral cavity. Virulence. 2015;6(3):244–8.

28. O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31(5):543–50.

29. Dahlstrom KR, Garden AS, William WN Jr, Lim MY, Sturgis EM. Proposed staging system for patients with HPV-related oropharyngeal cancer based on nasopharyngeal Cancer N categories. J Clin Oncol. 2016;34(16):1848–54.

30. Bonner JA, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J Clin Oncol. 2015;34(12):1300–8.